5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID
Furosemide
CAS: 54-31-9
Molecular Formula: C12H11ClN2O5S
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Names and Identifiers
| Name | Furosemide |
| Synonyms | Frusemide FRUSEMIDE FUROSEMID FUROSEMIDE Furosemide LABOTEST-BB LT00244801 4-CHLORO-N-FURFURYL-5-SULFAMOYLANTHRANILIC ACID 4-chloro-n-furfuryl-5-sulfamoylanthranilic acid 2-furfurylamino-4-chloro-5-sulfamoylbenzoic acid 2-furfurylamino-4-chloro-5-sulfamoylbenzoic acid 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoic acid 5-[AMINOSULFONYL]-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID 5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID |
| CAS | 54-31-9 |
| EINECS | 200-203-6 |
| InChI | InChI=1/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19) |
| InChIKey | ZZUFCTLCJUWOSV-UHFFFAOYSA-N |
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Physico-chemical Properties
| Molecular Formula | C12H11ClN2O5S |
| Molar Mass | 330.74 |
| Density | 1.606 |
| Melting Point | 220 °C (dec.) (lit.) |
| Boling Point | 582.1±60.0 °C(Predicted) |
| Flash Point | 11°C |
| Water Solubility | Soluble in acetone, DMF or methanol. Slightly soluble in water |
| Solubility | Practically insoluble in water, soluble in acetone, sparingly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. It dissolves in dilute solutions of alkali hydroxides. |
| Appearance | powder |
| Color | White to Off-White |
| Merck | 14,4309 |
| pKa | pKa 3.8 (Uncertain) |
| Storage Condition | 2-8°C |
| Stability | Stable, but light sensitive, air sensitive and hygroscopic. Incompatible with strong oxidizing agents. |
| Refractive Index | 1.6580 (estimate) |
| Physical and Chemical Properties | Density 1.606 melting point 220°C |
| Use | Used as a diuretic |
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Risk and Safety
| Risk Codes | R61 - May cause harm to the unborn child R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S7 - Keep container tightly closed. S16 - Keep away from sources of ignition. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S22 - Do not breathe dust. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| UN IDs | UN 1230 3/PG 2 |
| WGK Germany | 3 |
| RTECS | CB2625000 |
| HS Code | 2935904000 |
| Toxicity | LD50 orally in female, male rats: 2600, 2820 mg/kg (Goldenthal) |
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Standard
Authoritative Data Verified Data
This product is 2-[(2-furylmethyl) amino]-5-(sulfamoyl)-4-benzoic acid. Calculated as dry product, containing C12HUC1N205S shall not be less than 99.0%.
Last Update：2024-01-02 23:10:35
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Trait
Authoritative Data Verified Data
- This product is white or white crystalline powder; Odorless.
- This product is dissolved in acetone, slightly soluble in ethanol, insoluble in water.
melting point
The melting point of this product (General rule 0612) is 208~213°C, and it is decomposed at the same time during melting.
absorption coefficient
take this product, precision weighing, add 0.4% sodium hydroxide solution to dissolve and quantitatively dilute to make a solution containing about 10ug per lml, according to UV-visible spectrophotometry (General 0401), the absorbance was measured at a wavelength of 271nm, and the absorption coefficient was 565 to 595.
Last Update：2022-01-01 11:56:44
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Differential diagnosis
Authoritative Data Verified Data
- take about 25mg of this product, add 5ml of water, add sodium hydroxide test solution Dropwise to dissolve it, and add 1-2 drops of copper sulfate test solution to generate green precipitate.
- take 25mg of this product, put it in a test tube, add 2.5ml of ethanol to dissolve, add 2ml of p-dimethylaminobenzaldehyde test solution Dropwise along the tube wall, which shows green and gradual deep red.
- take this product, add 0.4% sodium hydroxide solution to make a solution containing about 5ug per lml, according to UV-visible spectrophotometry (General 0401), at 228nm, 271nm and 333nm wavelength has the maximum absorption.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 184).
Last Update：2022-01-01 11:56:44
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Exam
Authoritative Data Verified Data
clarity and color of alkaline solution
take 0.50g of this product, add 5ml of sodium hydroxide solution to dissolve, add 5ml of water, the solution should be clear and colorless; If it is turbid, compare with No. 2 Turbidity standard solution (General rule 0902 method 1), shall not be more concentrated; If the color is developed, it shall not be deeper in comparison with the yellow No. 3 Standard Colorimetric solution (General Principles 0901 first method).
chloride
take 2.og of this product, add 100ml of water, fully shake, filter; Take the filtrate 25ml, check according to law (General rule 0801), and compare with the control solution made of 7.0ml of standard sodium chloride solution, no more concentrated (0.014%).
sulfate
take 25ml of the filtrate remaining under the above chloride item, and check it according to law (General 0802). Compared with the control solution made of 2.0 ml of standard potassium sulfate solution, it should not be more concentrated (0.04%).
Related substances
operation in the dark. Take this product, add a mixed solvent [take glacial acetic acid 22ml, add acetonitrile-water (1:1) to 1000ml, mix evenly] dissolve and dilute to prepare a solution containing about 1 mg per 1 ml, as a test solution; An appropriate amount was taken in a precise amount and quantitatively diluted with a mixed solvent to prepare a solution containing log per 1 ml as a control solution. According to the high performance liquid phase determination (General 0512) test, using the eighteen alkyl silane bonded silica gel as the filler, water-tetrahydrofuran-glacial acetic acid (70:30:1) as the mobile phase, the detection wavelength was 272nm. The number of theoretical plates is not less than 4000 based on the furosemide peak. 20ul of the test solution and the control solution are respectively injected into the liquid chromatograph, and the chromatogram is recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the single impurity peak area shall not be greater than 0.2 times (0.2%) of the main peak area of the control solution, and the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
not more than 0.1% (General rule 0841).
Heavy metals
take 0.50g of this product, inspection according to law (General rule 0821 third law), containing heavy metals shall not exceed 20 parts per million.
arsenic salt
take this product l.Og, add lg of calcium hydroxide, add a small amount of water, stir evenly, first heat with small fire, then burn to complete Ash, let cool, add 5ml of hydrochloric acid and 23ml of water, inspection according to law (General Principles 0822 first law), shall comply with the provisions (0.0002%).
Last Update：2022-01-01 11:56:45
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Content determination
Authoritative Data Verified Data
take this product about 0.5g, precision weighing, add ethanol 30ml, slightly warm to dissolve, cool, add 4 drops of Cresol red indicator solution and 1 drop of Thymol blue indicator solution, with sodium hydroxide titration solution (0.1 mol/L) titration to the solution is purplish red, and the result of the titration is corrected with the blank test. Each 1 ml of sodium hydroxide titration solution (0.1 mol/L) corresponds to 33.07mg of c12h11c1n205 s.
Last Update：2022-01-01 11:56:46
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Category
Authoritative Data Verified Data
diuretics.
Last Update：2022-01-01 11:56:46
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 11:56:46
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Furosemide Tablets
Authoritative Data Verified Data
This product contains furosemide (C12H11C1N205S) should be the label amount of 90.0% ~ 110.0%.
trait
This product is white tablet.
identification
take an appropriate amount of fine powder of this product (about 80mg equivalent to furosemide), add 10ml of ethanol, shake to dissolve furosemide, filter, evaporate the filtrate, identify the residue according to furosemide (1), (2), (3) test, showing the same results.
examination
- dissolution: take this product as the dissolution and release determination method (General rule 0931 second method), and use phosphate buffer (pH 5.8) 1000ml as the dissolution medium at 50 rpm, operate in accordance with the law, after 30 minutes, take the appropriate amount of solution, filter, Take 5ml of the filtrate, put it in a 10ml measuring flask, dilute it with 0.8% sodium hydroxide solution to the scale, shake well, the absorbance was measured at a wavelength of 271nm according to UV-Vis spectrophotometry (General rule 0401), and the elution amount of each tablet was calculated as the absorption coefficient of C12H11C1N205S was 580. The limit is 65% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
Take 20 tablets of this product, precision weighing, fine grinding, precision weighing appropriate amount (about equivalent to Furosemide 20mg), put it in a 100ml measuring flask, add 0.4% sodium hydroxide solution about 60ml, shake for 10 minutes to dissolve furosemide, dilute to the scale with 0.4% sodium hydroxide solution, shake well, filter, Take 5ml of filtrate accurately, place it in another 100ml measuring flask, dilute with 0.4% sodium hydroxide solution to the scale, shake, according to UV-visible spectrophotometry (General 0401), at the wavelength of 271mn absorbance, according to C12H11C1N205S absorption coefficient of 580 calculation, that's right.
category
Same as furosemide.
specification
20mg
storage
light-shielded, sealed, and stored in a dry place.
Last Update：2022-01-01 11:56:46
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Furosemide Tablets
Authoritative Data Verified Data
This product is a sterile aqueous solution made of furosemide plus sodium hydroxide and sodium chloride. The content of furosemide (C12H11C1N205S) shall be between 90.0% and 110.0% of the labeled amount.
trait
This product is colorless or almost colorless clear liquid.
identification
This product was taken, and the same results were shown according to the tests of (1), (2) and (3) under the item of furosemide.
examination
- the pH value should be 8.5 to 9.5 (General 0631).
- the related substances were protected from light. Take an appropriate amount of this product, dilute with a mixed solvent [take glacial acetic acid 22ml, add acetonitrile-water (1:1) to 1000ml, mix well] to make a solution containing about 1 mg per 1 ml, as a test solution; An appropriate amount was taken in a precise amount and quantitatively diluted with a mixed solvent to prepare a solution containing 10ug per 1 ml as a control solution. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than 1.5 times (1.5%) the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 3 times (3.0%) of the main peak area of the control solution.
- the bacterial endotoxin of this product is taken and checked according to law (General rule 1143). The amount of endotoxin contained in 1 mg furosemide should be less than 1.2EU.
- others should comply with the relevant provisions under injection (General 0102).
Content determination
- The measurement was performed according to a high performance liquid chromatography method (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Water-tetrahydrofuran-glacial acetic acid (70:30:1) as mobile phase; The detection wavelength was 272nm. The number of theoretical plates is not less than 4000 based on the furosemide peak.
- determination of precision take appropriate amount of this product, with a mixed solvent [22ml of glacial acetic acid, add acetonitrile-water (1:1) to 1000ml, mixing] Quantitative dilution to make furosemide content of about 0 per 1 ml. lmg solution, the precision of 20u1 injection of human liquid chromatography, record chromatogram; Another furosemide reference substance, the same method for determination. According to the external standard method to calculate the peak area, that is.
category
Same as furosemide.
specification
2ml:20mg
storage
light shielding, closed storage.
Last Update：2022-01-01 11:56:47
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Fuluobi (Compound Furosemide Tablets)
Authoritative Data Verified Data
This product contains furosemide (C12H11C1N205S) and amiloride hydrochloride (C6H8CIN70 • HCI) should be 90.0% ~ 110.0% of the label amount.
prescription
Furosemide 20g
Amiloride hydrochloride 2.5G
Appropriate amount of excipients
Made into 1000 tablets
trait
This product is white-like to yellowish.
identification
- take an appropriate amount of fine powder of this product (equivalent to furosemide 80mg), add 10ml of ethanol, shake to dissolve furosemide and amiloride hydrochloride, filter, evaporate the filtrate, take the residue about 25mg, add 2-dimethylaminobenzaldehyde test solution (2ml) along the tube wall. The solution is green and gradually deep red.
- in the chromatogram recorded under the content determination item, the retention time of the two main peaks of the test solution should be consistent with the retention time of the corresponding two main peaks of the control solution.
- take about 20mg of the residue under Item (1) of identification, add 20ml of water to dissolve, add excess nitric acid Dropwise to complete precipitation, filter, filtrate chloride identification (1) response (General rule 0301).
examination
- Content uniformity take 1 tablet of this product, put it in a 100ml measuring flask, add methanol 10ml and 0.2ml of 1 mol/L hydrochloric acid solution, fully shake to dissolve furosemide and amiloride hydrochloride, dilute to the scale with mobile phase, shake, filter, and take the continued filtrate as the test solution, determination of furosemide and salt dissolution according to the method under the item of content determination this product, according to the dissolution and release determination method (General 0931 second method), phosphate buffer solution (pH 5.8)900ml is the dissolution medium, the rotation speed is 50 revolutions per minute, and the operation is carried out according to law. After 30 minutes, the appropriate amount of the solution is taken, filtered, and the filtrate is taken as the test solution. 5ml of the reference solution under the content measurement item was accurately measured, placed in a 50ml measuring flask, diluted to the scale with the dissolution medium, and shaken to obtain the reference solution. The dissolution amounts of furosemide and amiloride hydrochloride per tablet were calculated respectively by taking the above two kinds of solutions and measuring according to the chromatographic conditions under the content determination item. The limit shall be 75% of the labeled amount and shall be in accordance with the regulations.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Water-methanol-phosphate buffer (take potassium dihydrogen phosphate 13.6g, add water 80ml to dissolve, the pH was adjusted to 3.0 with phosphoric acid, diluted to ML with water)(50:49:1) as mobile phase; The detection wavelength was 286nm. The number of theoretical plates shall not be less than 2000 based on the furosemide peak. The separation degree of furosemide peak and amiloride peak shall meet the requirements.
- determination of 20 tablets of this product, precision weighing, fine, precision weighing an appropriate amount (equivalent to furosemide 40mg and amiloride hydrochloride 5mg ), put in a 200ml measuring flask, add 15ml of methanol with O. 1 mol/L hydrochloric acid solution 2ml, ultrasonic about 15 minutes to dissolve furosemide and amiloride hydrochloride, let it cool, dilute to the scale with mobile phase, shake, filter, take the filtrate as the test solution, 20ul for precision measurement, injection of human liquid chromatograph, record chromatogram; Amiloride hydrochloride reference substance, precision weighing, add methanol to dissolve and quantitatively dilute to prepare a solution containing about 1 mg per 1 ml as a reference solution (1); Take another furosemide reference about 40mg, weigh it accurately, and put it in a 200ml measuring flask, add 15ml methanol and 0.1 mol/L hydrochloric acid solution 2ml, ultrasonic about 15 minutes, cool, and then precision plus the control solution (l)5ml, diluted with mobile phase to the scale, shake, as a reference solution, the same method. The contents of furosemide and amiloride hydrochloride were calculated by peak area according to external standard method.
category
diuretics.
storage
light shielding, sealed storage.
Last Update：2022-01-01 13:43:22
5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID - Reference Information
| (IARC) carcinogen classification | 3 (Vol. 50) 1990 |
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| Introduction | furosemide is a diuretic, also known as furosemide, developed in 1963 by the former sidehst, clinically used for the treatment of cardiac edema, renal edema, liver cirrhosis ascites, dysfunction or vascular disorders caused by peripheral edema, and can promote the upper urethral calculi discharge. Its diuretic effect is rapid and strong, and it is often used in severe cases where other diuretics are ineffective. |
| high-efficiency diuretics | furosemide, also known as furanilianic acid, furosemide, furosemide, diuretics, is a role in the ascending branch of the medullary branch of the sulfamide class of highly efficient diuretics, has a strong and short diuretic effect, can increase water, sodium, chlorine, potassium, calcium, magnesium, excretion of phosphate, etc. Clinically used for the treatment of cardiac edema, renal edema, cirrhosis ascites, dysfunction or vascular disorders caused by peripheral edema, and can promote the upper urinary tract calculi excretion. Intravenous administration can treat cerebral edema, and can also accelerate the excretion of toxic substances in the case of cerebral edema. It should be noted that furosemide diuresis, due to the increase in urine Cl-, Na, K, H excretion, the excretion of HCO3-does not increase, long-term repeated use or a large number of drugs can cause low salt syndrome, low chlorine and low potassium base poisoning. In recent years, researchers have found that furosemide aerosol inhalation has obvious Antiasthmatic effect, which is the same as sodium cromoglycate, inhibits the release of allergic mediators, inhibits the release of neurotransmitter acetylcholine and substance P, it may be related to its ability to inhibit the entry of chloride ions into the cell membrane of the respiratory tract. Clinical trials in exercise-induced asthma, antigen-induced immediate and late-onset asthma. |
| mechanism of action | furosemide mainly inhibits the reabsorption of Na and Cl-in the medulla and cortex of the thick ascending branch of the loop, promoting sodium, chloride, the excretion of potassium and affects the formation of hyperosmolality in the renal medulla, interferes with the process of concentration and dilution of urine, increases the volume of urine. This product can inhibit the activity of prostaglandin decomposition enzyme, increase the content of prostaglandin E2, has the effect of expanding blood vessels, has the effect of proximal convoluted tubules and glomerular filtration, and can increase renal blood flow, adjust the blood flow distribution in the kidney, reduce the blood flow of the medulla, increase the blood flow of the surface cortex, promote diuresis, the effect is rapid and strong, and it is used for other cases of ineffective diuretic drugs. |
| pharmacokinetics | The oral absorption rate of furosemide is 60% ~ 70%, but it does not affect the absorption rate and its curative effect. The oral absorption rate of patients with end-stage renal disease is reduced to 43% ~ 46%. Congestive heart failure and nephrotic syndrome and other edema diseases, due to intestinal wall edema, oral absorption rate also decreased, so in the above situation should be parenteral route of administration. Mainly distributed in the extracellular fluid, the volume of distribution of the average body weight of 11.4%, plasma protein binding rate of 91% ~ 97%, almost all with albumin binding. The drug can pass through the placental barrier and can be secreted into the milk. The onset time of action after oral and intravenous administration was 30-60 minutes and 5 minutes, respectively, and the peak time was 1-2 hours and 0.33-1 hours. The duration of action was 6-8 hours and 2 hours, respectively. There is a large individual difference in T1/2b, the normal person is 30~60 minutes, anuria patients extended to 75~155 minutes, liver and kidney function at the same time severe damage extended to 11~20 hours. Due to the poor liver and kidney clearance ability, T1/2b was prolonged to 4~8 hours. 88% to the original form of renal excretion, 12% by the liver metabolism by bile excretion. Impaired renal function increased metabolism by the liver. The drug was not cleared by dialysis. |
| indications | (1) edema diseases including congestive heart failure, liver cirrhosis, kidney disease (nephritis, kidney disease and various causes of acute and chronic renal failure), especially when the effect of other diuretics is not good, the application of this class of drugs may still be effective. Combined with other drugs in the treatment of acute pulmonary edema and acute cerebral edema. (2) hypertension is generally not the first choice for the treatment of essential hypertension, but when the efficacy of thiazide drugs is poor, especially when accompanied by renal insufficiency or hypertensive crisis, this class of drugs is particularly suitable. (3) prevention of acute renal failure for a variety of reasons lead to insufficient renal blood perfusion, such as water loss, Shock, poisoning, anesthesia accident and circulatory insufficiency, in the correction of hypovolemia and timely application, can reduce the chance of acute tubular necrosis. (4) hyperkalemia and hypercalcemia. (5) Diluted hyponatremia, especially when the serum sodium concentration is lower than 120mmol/L. (6) SIADH. (7) Acute drug poisoning such as barbiturate poisoning. |
| side effects | during the use of furosemide, there may be Nausea, Diarrhea, drug eruption, pruritus, blurred vision and other adverse reactions, sometimes can occur dizziness, Fatigue, fatigue, muscle cramps, thirst, a small number of patients with leukopenia, individual patients with thrombocytopenia, erythema multiforme, orthostatic hypotension, long-term use can cause gastric and duodenal ulcers. |
| Use | The drug has a strong and short diuretic effect, and is a potent diuretic for the treatment of heart, liver, edema caused by diseases such as kidney, especially the case of no effect on the basal diuretic drugs; Can be used for the treatment of acute pulmonary edema, cerebral edema, acute renal failure and hypertension and other diseases; With the rehydration of the product can promote the toxic non-discharge. The oral LD50 of rats was 2600-2820mg/kg. use as diuretic |
| production method | 2, 4-dichlorobenzoic acid (see 12740) is obtained by chlorosulfonation, ammonification and acidification, 4-dichloro-5-sulfamoylbenzoic acid. Furosemide is then prepared by condensation with furfurylamine. |
| category | toxic substances |
| toxicity grade | poisoning |
| Acute toxicity | oral-rat LD50: 2600 mg/kg; Oral-mouse LD50: 2200 mg/kg |
| flammability hazard characteristics | flammable; Decomposition of toxic nitrogen oxides in fire; sulfur oxide and chloride fumes |
| storage and transportation characteristics | warehouse low temperature, ventilation, dry |
| extinguishing agent | water, carbon dioxide, dry powder, sand |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-09 19:05:07
![5-(AMINOSULPHONYL)-4-CHLORO-2-[(2-FURANYLMETHYL)AMINO]BENZOIC ACID](http://res.chembk.com/assets/str/2d/5/54/54-31-9.png)
Supplier List
Featured ProductsMultiple Specifications
Product Name: Furosemide Request for quotationCAS: 54-31-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Spot supply
Product Name: Furosemide Visit Supplier Webpage Request for quotationCAS: 54-31-9
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Furosemide Request for quotation
CAS: 54-31-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 54-31-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Featured ProductsMultiple Specifications
Product Name: Furosemide Request for quotationCAS: 54-31-9
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Spot supply
Product Name: Furosemide Visit Supplier Webpage Request for quotationCAS: 54-31-9
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Product Name: Furosemide Request for quotation
CAS: 54-31-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 54-31-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
View History